Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 15-Mar-24 7:23 PM View:  | Booth Bruce Director | Kymera Therapeutics, Inc. (KYMR) | 15-Mar-24 | Sale (Planned) | 71,764 | $40.46 | $2,903,340.00 | (1%) 5.45M to 5.38M | |
| 15-Mar-24 7:23 PM View: | Booth Bruce Director | Kymera Therapeutics, Inc. (KYMR) | 14-Mar-24 | Sale (Planned) | 55,779 | $39.98 | $2,229,930.00 | (1%) 5.5M to 5.45M | |
| 13-Mar-24 7:53 PM View: | Atlas Venture Fund X, L.P. 10% Owner | Kymera Therapeutics, Inc. (KYMR) | 13-Mar-24 | Sale (Planned) | 115,090 | $42.23 | $4,859,990.00 | (2%) 5.64M to 5.53M | |
| 13-Mar-24 7:52 PM View: | Booth Bruce Director | Kymera Therapeutics, Inc. (KYMR) | 13-Mar-24 | Sale (Planned) | 139,255 | $42.23 | $5,880,420.00 | (2%) 5.64M to 5.5M | |
| 13-Mar-24 7:53 PM View: | Atlas Venture Fund X, L.P. 10% Owner | Kymera Therapeutics, Inc. (KYMR) | 13-Mar-24 | Sale (Planned) | 24,165 | $42.23 | $1,020,420.00 | (< 1%) 5.53M to 5.5M | |
| 13-Mar-24 7:52 PM View: | Booth Bruce Director | Kymera Therapeutics, Inc. (KYMR) | 12-Mar-24 | Sale (Planned) | 162,918 | $41.98 | $6,838,810.00 | (3%) 5.81M to 5.64M | |
| 13-Mar-24 7:53 PM View: | Atlas Venture Fund X, L.P. 10% Owner | Kymera Therapeutics, Inc. (KYMR) | 12-Mar-24 | Sale (Planned) | 134,647 | $41.98 | $5,652,070.00 | (2%) 5.81M to 5.67M | |
| 13-Mar-24 7:53 PM View: | Atlas Venture Fund X, L.P. 10% Owner | Kymera Therapeutics, Inc. (KYMR) | 12-Mar-24 | Sale (Planned) | 28,271 | $41.98 | $1,186,740.00 | (< 1%) 5.67M to 5.64M | |
| 13-Mar-24 7:53 PM View: | Atlas Venture Fund X, L.P. 10% Owner | Kymera Therapeutics, Inc. (KYMR) | 11-Mar-24 | Sale (Planned) | 8,882 | $42.85 | $380,562.00 | (< 1%) 5.82M to 5.81M | |
| 13-Mar-24 7:53 PM View: | Atlas Venture Fund X, L.P. 10% Owner | Kymera Therapeutics, Inc. (KYMR) | 11-Mar-24 | Sale (Planned) | 42,302 | $42.85 | $1,812,590.00 | (< 1%) 5.86M to 5.82M | |
| 13-Mar-24 7:52 PM View: | Booth Bruce Director | Kymera Therapeutics, Inc. (KYMR) | 11-Mar-24 | Sale (Planned) | 51,184 | $42.85 | $2,193,150.00 | (< 1%) 5.86M to 5.81M | |
| 04-Mar-24 6:21 PM View: | Gollob Jared Chief Medical Officer | Kymera Therapeutics, Inc. (KYMR) | 04-Mar-24 | Sale | 3,344 | $41.86 | $139,967.00 | (3%) 99.08K to 95.74K | |
| 04-Mar-24 6:12 PM View: | Jacobs Bruce N. Chief Financial Officer | Kymera Therapeutics, Inc. (KYMR) | 04-Mar-24 | Sale | 3,934 | $41.86 | $164,664.00 | (3%) 146.28K to 142.35K | |
| 04-Mar-24 6:16 PM View: | Chadwick Jeremy G Chief Operating Officer | Kymera Therapeutics, Inc. (KYMR) | 01-Mar-24 | Grant | 13,425 | -- | -- | 40% 33.33K to 46.76K | |
| 04-Mar-24 6:15 PM View: | Chiniara Ellen Chief Legal Officer | Kymera Therapeutics, Inc. (KYMR) | 01-Mar-24 | Grant | 21,755 | -- | -- | 64% 34.2K to 55.96K | |
| 04-Mar-24 6:21 PM View: | Gollob Jared Chief Medical Officer | Kymera Therapeutics, Inc. (KYMR) | 01-Mar-24 | Grant | 24,375 | -- | -- | 33% 74.71K to 99.08K | |
| 04-Mar-24 6:12 PM View: | Jacobs Bruce N. Chief Financial Officer | Kymera Therapeutics, Inc. (KYMR) | 01-Mar-24 | Grant | 31,250 | -- | -- | 27% 115.03K to 146.28K | |
| 29-Feb-24 10:00 PM View: | Gollob Jared Chief Medical Officer | Kymera Therapeutics, Inc. (KYMR) | 27-Feb-24 | Option Exercise | 400 | $2.08 | $832.00 | < 1% 74.71K to 75.11K | |
| 29-Feb-24 10:00 PM View: | Gollob Jared Chief Medical Officer | Kymera Therapeutics, Inc. (KYMR) | 27-Feb-24 | Planned Option Sale | 400 | $45.00 | $18,000.00 | (< 1%) 75.11K to 74.71K | |
| 21-Feb-24 6:46 PM View: | Albers Jeffrey W. Director | Kymera Therapeutics, Inc. (KYMR) | 21-Feb-24 | Planned Option Sale | 4,385 | $39.05 | $171,227.00 | (100%) 4.38K to 0 | |
| 21-Feb-24 6:46 PM View: | Albers Jeffrey W. Director | Kymera Therapeutics, Inc. (KYMR) | 21-Feb-24 | Option Exercise | 4,385 | $10.34 | $45,340.90 | 100% 0 to 4.38K | |
| 21-Feb-24 6:46 PM View: | Albers Jeffrey W. Director | Kymera Therapeutics, Inc. (KYMR) | 20-Feb-24 | Option Exercise | 615 | $10.34 | $6,359.10 | 100% 0 to 0.61K | |
| 21-Feb-24 6:46 PM View: | Albers Jeffrey W. Director | Kymera Therapeutics, Inc. (KYMR) | 20-Feb-24 | Planned Option Sale | 615 | $39.07 | $24,030.90 | (100%) 0.61K to 0 | |
| 09-Feb-24 7:47 PM View: | Gollob Jared Chief Medical Officer | Kymera Therapeutics, Inc. (KYMR) | 09-Feb-24 | Planned Option Sale | 46,137 | $35.50 | $1,638,070.00 | (38%) 120.85K to 74.71K | |
| 09-Feb-24 7:47 PM View: | Gollob Jared Chief Medical Officer | Kymera Therapeutics, Inc. (KYMR) | 09-Feb-24 | Option Exercise | 46,137 | $2.08 | $95,965.00 | 62% 74.71K to 120.85K | |
| 23-Jan-24 7:37 PM View: | Albers Jeffrey W. Director | Kymera Therapeutics, Inc. (KYMR) | 23-Jan-24 | Option Exercise | 10,000 | $10.34 | $103,400.00 | 100% 0 to 10.0K | |
| 23-Jan-24 7:37 PM View: | Albers Jeffrey W. Director | Kymera Therapeutics, Inc. (KYMR) | 23-Jan-24 | Planned Option Sale | 10,000 | $30.05 | $300,470.00 | (100%) 10.0K to 0 | |
| 05-Jan-24 5:15 PM View: | Chiniara Ellen Chief Legal Officer | Kymera Therapeutics, Inc. (KYMR) | 04-Jan-24 | Sale | 3,295 | $22.58 | $74,415.60 | (9%) 37.5K to 34.2K | |
| 02-Jan-24 5:43 PM View: | Mainolfi Nello Chief Executive Officer Director | Kymera Therapeutics, Inc. (KYMR) | 02-Jan-24 | Option Exercise | 9,000 | $2.08 | $18,720.00 | 1% 606.57K to 615.57K | |
| 06-Nov-23 6:00 PM View: | Mainolfi Nello Chief Executive Officer Director | Kymera Therapeutics, Inc. (KYMR) | 03-Nov-23 | Option Exercise | 20,000 | $2.08 | $41,600.00 | 3% 586.57K to 606.57K | |
| 06-Nov-23 6:07 PM View: | Bvf Partners L P/il Director | Kymera Therapeutics, Inc. (KYMR) | 03-Nov-23 | Purchase | 197,699 | $14.07 | $2,781,410.00 | 4% 4.86M to 5.05M | |
| 06-Nov-23 6:07 PM View: | Bvf Partners L P/il Director | Kymera Therapeutics, Inc. (KYMR) | 02-Nov-23 | Private Purchase | 216,406 | $11.64 | $2,519,920.00 | 5% 4.64M to 4.86M | |
| 08-Aug-23 4:30 PM View: | Mainolfi Nello Chief Executive Officer Director | Kymera Therapeutics, Inc. (KYMR) | 08-Aug-23 | Option Exercise | 12,000 | $2.08 | $24,960.00 | 2% 574.57K to 586.57K | |
| 02-Jun-23 2:17 PM View: | Jacobs Bruce N. Chief Financial Officer | Kymera Therapeutics, Inc. (KYMR) | 02-Jun-23 | Option Exercise | 10,000 | $2.08 | $20,800.00 | 10% 105.03K to 115.03K | |
| 22-May-23 7:35 PM View: | Chadwick Jeremy G Chief Operating Officer | Kymera Therapeutics, Inc. (KYMR) | 22-May-23 | Grant | 33,333 | -- | -- | 100% 0 to 33.33K | |
| 03-Mar-23 10:00 PM View: | Gollob Jared Chief Medical Officer | Kymera Therapeutics, Inc. (KYMR) | 02-Mar-23 | Sale (Planned) | 1,298 | $31.00 | $40,233.30 | (2%) 76.01K to 74.71K | |
| 03-Mar-23 4:30 PM View: | Jacobs Bruce N. Chief Financial Officer | Kymera Therapeutics, Inc. (KYMR) | 02-Mar-23 | Sale (Planned) | 1,370 | $31.00 | $42,465.30 | (1%) 105.94K to 104.57K | |
| 03-Mar-23 4:31 PM View: | Caughey Elaine Chief Business Officer | Kymera Therapeutics, Inc. (KYMR) | 02-Mar-23 | Sale (Planned) | 714 | $31.00 | $22,131.70 | (4%) 19.7K to 18.99K | |
| 03-Mar-23 4:30 PM View: | Jacobs Bruce N. Chief Financial Officer | Kymera Therapeutics, Inc. (KYMR) | 01-Mar-23 | Grant | 23,750 | -- | -- | 29% 82.19K to 105.94K | |
| 03-Mar-23 10:00 PM View: | Gollob Jared Chief Medical Officer | Kymera Therapeutics, Inc. (KYMR) | 01-Mar-23 | Grant | 18,750 | -- | -- | 33% 57.26K to 76.01K | |
| 03-Mar-23 4:31 PM View: | Caughey Elaine Chief Business Officer | Kymera Therapeutics, Inc. (KYMR) | 01-Mar-23 | Grant | 10,557 | -- | -- | 115% 9.14K to 19.7K | |
| 13-Jan-23 4:50 PM View: | Atlas Venture Fund X, L.P. 10% Owner | Kymera Therapeutics, Inc. (KYMR) | 12-Jan-23 | Sale (Planned) | 21,592 | $30.29 | $654,022.00 | (< 1%) 5.88M to 5.86M | |
| 13-Jan-23 4:53 PM View: | Booth Bruce Director | Kymera Therapeutics, Inc. (KYMR) | 12-Jan-23 | Sale (Planned) | 98,720 | $30.29 | $2,990,230.00 | (2%) 5.96M to 5.86M | |
| 13-Jan-23 5:08 PM View: | Bvf Partners L P/il Director | Kymera Therapeutics, Inc. (KYMR) | 12-Jan-23 | Purchase | 18,897 | $31.24 | $590,391.00 | < 1% 4.62M to 4.64M | |
| 13-Jan-23 4:50 PM View: | Atlas Venture Fund X, L.P. 10% Owner | Kymera Therapeutics, Inc. (KYMR) | 12-Jan-23 | Sale (Planned) | 77,128 | $30.29 | $2,336,210.00 | (1%) 5.96M to 5.88M | |
| 13-Jan-23 4:53 PM View: | Booth Bruce Director | Kymera Therapeutics, Inc. (KYMR) | 11-Jan-23 | Sale (Planned) | 27,754 | $29.96 | $831,510.00 | (< 1%) 5.98M to 5.96M | |
| 13-Jan-23 4:50 PM View: | Atlas Venture Fund X, L.P. 10% Owner | Kymera Therapeutics, Inc. (KYMR) | 11-Jan-23 | Sale (Planned) | 21,683 | $29.96 | $649,623.00 | (< 1%) 5.98M to 5.96M | |
| 13-Jan-23 5:08 PM View: | Bvf Partners L P/il Director | Kymera Therapeutics, Inc. (KYMR) | 11-Jan-23 | Private Purchase | 22,110 | $29.89 | $660,799.00 | < 1% 4.6M to 4.62M | |
| 13-Jan-23 4:50 PM View: | Atlas Venture Fund X, L.P. 10% Owner | Kymera Therapeutics, Inc. (KYMR) | 11-Jan-23 | Sale (Planned) | 6,071 | $29.96 | $181,887.00 | (< 1%) 5.96M to 5.96M | |
| 04-Jan-23 4:35 PM View: | Chiniara Ellen Chief Legal Officer | Kymera Therapeutics, Inc. (KYMR) | 03-Jan-23 | Grant | 37,500 | -- | -- | 100% 0 to 37.5K |
